Statements (12)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:microbiome_therapeutic
|
| gptkbp:clinicalTrialPhase |
Phase 2
|
| gptkbp:composition |
consortium of bacterial spores
|
| gptkbp:developedBy |
gptkb:Seres_Therapeutics
|
| gptkbp:indication |
ulcerative colitis
|
| gptkbp:mechanismOfAction |
modulation of gut microbiome
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:status |
investigational
|
| gptkbp:targetAudience |
patients with mild-to-moderate ulcerative colitis
|
| gptkbp:bfsParent |
gptkb:Seres_Therapeutics
|
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
SER-287
|